<DOC>
	<DOC>NCT00845663</DOC>
	<brief_summary>To compare the bioavailability of a single 400 mg dose of certolizumab pegol solution (2 x 200mg subcutaneous injections) injected either by a pre-filled syringe (reference) or by an auto-injection device (test).</brief_summary>
	<brief_title>Comparison Bioequivalence Study: Pre-filled Syringe (Reference) Versus Auto-injection Device (Test)</brief_title>
	<detailed_description />
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Age: 1855 years. A Body mass Index (BMI) of 18 to 28 kg/m Good physical and mental health status determined on the basis of the medical history and a general clinical examination Electrocardiogram and clinical laboratory tests interpreted as "normal" QuantiFERONTB test negative female subjects: medically accepted method of contraception prohibited concomitant medication administered vaccines and immunoglobulins in the month preceding the certolizumab pegol injection history of significant disease, allergies history of drug and/or alcohol abuse hepatic enzyme inducing drug within 2 months before study drug administration any drugs having influence of the immune response and antibiotic in the month preceding the inclusion known to be intolerant to PEG previously received certolizumab pegol previously received an antibody product within 5half lives of the antibody or within 3 months of the start of the study history of tuberculosis have serum hepatitis or is carrier of the Hepatitis B surface antigen (HBs Ag), or Hepatitis C antibody or who is HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>certolizumab pegol</keyword>
	<keyword>Cimzia</keyword>
	<keyword>bioequivalence</keyword>
	<keyword>Comparison Bioequivalence Study</keyword>
</DOC>